



NDA 205103/S-1

SUPPLEMENT APPROVAL

Aralez Pharmaceuticals Trading DAC
C/o Mapi USA, Inc
Attention: Jennifer Sanguedolce, MS., RAC
Senior Manager, US Regulatory Affairs
2343 Alexandria Drive
Lexington, KY 40504

Dear Ms. Sanguedolce:

Please refer to your Supplemental New Drug Application (sNDA) dated April 5, 2017, received April 5, 2017, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Yosprala delayed-release tablets (aspirin 81 mg/omeprazole 40 mg, and aspirin 325 mg/omeprazole 40 mg).

We also refer to our letter dated March 7, 2017, notifying you of changes made to the label of the referenced listed drug, Prilosec (omeprazole magnesium), approved on October 24, 2016, and requesting a Prior Approval Supplement for Yosprala. The changes pertain to the risk of serious cutaneous and systemic lupus erythematosus events associated with the use of PPIs.

This supplemental new drug application provides for revisions to the Warnings and Precautions section of the Prescribing Information and the Medication Guide for Yosprala, consistent with the approved prescribing Information (PI) and Medication Guide (MG) for Prilosec (omeprazole magnesium) dated October 2016.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text and with the minor editorial revisions indicated in the enclosed labeling.

WAIVER OF HIGHLIGHTS SECTION

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to, except with the revisions indicated, the enclosed labeling (text for the package insert, Medication Guide) with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes with the revisions indicated above approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at:

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf>).

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>.

Information and Instructions for completing the form can be found at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call CAPT Mimi T. Phan, Regulatory Project Manager, at (301) 796-5408.

Sincerely,

{See appended electronic signature page}

Joyce Korvick, M.D., M.P.H

Deputy Director for Safety

Division of Gastroenterology and Inborn Errors
Products

Office of Drug Evaluation III

Center for Drug Evaluation and Research

ENCLOSURES: Content of Labeling -- Prescribing Information and Medication Guide

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOYCE A KORVICK
10/04/2017